NUVBNuvation Bio Inc.
$5.00+55% 1Y
$5.00
$3.0152 weeks$9.54
The financials
Nuvation Bio Inc. by the numbers
Nuvation Bio Inc. (NUVB) reported revenue of $32M in Q2 2026 (quarter ended Jun 30, 2026), up 556% from the same quarter a year earlier. That came with net loss of $63M. For the full year FY2025, revenue was $63M (+699% year on year) and net income −$205M. Its largest product in Q2 2026 was Product at $23M, 66% of the disclosed total, well ahead of License at 24%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $32M | $4.8M | +556% |
| Gross profit | n/a | $2.3M | n/a |
| Operating income | −$51M | −$64M | n/a |
| Net income | −$63M | −$59M | n/a |
| Diluted EPS | −$0.18 | −$0.17 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Product | $23M | 66% |
| License | $8.5M | 24% |
| Research And Development Service | $2.0M | 5.7% |
| Royalty | $1.6M | 4.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $35.3M (-59%)
Product grew +2800% year on yearResearch And Development Service -9.1% year on year
Segment Latestquarter on quarteryear on year
- Product$23.2M$23.2Mquarter on quarter +25%year on year +2800%+25%+2800%
- License$8.5M$8.5Mquarter on quarter -87%year on year +136%-87%+136%
- Research And Development Service$2.0M$2.0Mquarter on quarter +186%year on year -9.1%+186%-9.1%
- Royalty$1.6M$1.6Mquarter on quarter +14%year on year +700%+14%+700%
On our screens:Most shorted stocks